Skip to content
value.today

Tangen Biosciences, Inc.

🇺🇸 Branford, Connecticut, USABiotechnologyFounded 2013

Formerly Tangen Biosciences, LLC

Total raised
$20 M
3 rounds on record
Latest round
$11 M
Jun 2020
First round on record
Dec 2015
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tangen Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$11 MNo. 3$10 to $50 million

Tangen Biosciences, Inc.: Raise no. 3, Jun 2020

Investors in this round

39 investors had bought by the notice of Jul 1, 2020: 39 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $20 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$375,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Chirico · Executive Officer
  • John Davidson · Executive Officer, Director
  • Richard Birkmeyer, PhD · Executive Officer, Director
  • Christopher Benoit · Director
  • Christopher McLeod · Director
  • Dan Wagner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard Birkmeyer, PhD, President and CEO. Newest notice filed Jul 1, 2020. Read the notice at the SEC.

equity, debt, optionsSEC
Mar 2019$7 MNo. 2$2 to $10 million

Tangen Biosciences, Inc.: Raise no. 2, Mar 2019

Investors in this round

29 investors had bought by the notice of Mar 22, 2019: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $11 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$200,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Davidson · Executive Officer, Director
  • Richard Birkmeyer, PhD · Executive Officer, Director
  • Christopher Benoit · Director
  • Christopher McLeod · Director
  • Dan Wagner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard Birkmeyer, PhD, President and CEO. Newest notice filed Mar 22, 2019. Read the notice at the SEC.

equity, optionsSEC
Dec 2015$2 MNo. 1$2 to $10 million

Tangen Biosciences, Inc.: Raise no. 1, Dec 2015

Investors in this round

8 investors had bought by the notice of Dec 28, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Richard Davidson · Executive Officer, Director, Promoter
  • John Richard Nobile · Executive Officer, Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds of the offering may be used by the Issuer to pay the salaries of its executive officers in the ordinary course of business.”

Signed by John Richard Nobile, President. Newest notice filed Dec 28, 2015. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tangen Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).

    SEC Form D · Jul 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2020

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Tangen Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tangen Biosciences, Inc.
NameRoleNamed in
Brian ChiricoExecutive officerJul 2020
John DavidsonExecutive officerJul 2020
Richard Birkmeyer, PhDExecutive officerJul 2020
John Richard DavidsonExecutive officerDec 2015
John Richard NobileExecutive officerDec 2015
Christopher BenoitDirectorJul 2020
Christopher McLeodDirectorJul 2020
Dan WagnerDirectorJul 2020
John DavidsonDirectorJul 2020
Richard Birkmeyer, PhDDirectorJul 2020
John Richard DavidsonDirectorDec 2015
John Richard NobileDirectorDec 2015
John Richard DavidsonPromoterDec 2015
John Richard NobilePromoterDec 2015